Deupsilocin - Cybin
Alternative Names: CYB-003; Deuterated psilocin - Cybin; Deuterated-Psilocin - Cybin; HLP-003Latest Information Update: 09 Mar 2026
At a glance
- Originator Cybin
- Class Antidepressants; Antipsychotics; Behavioural disorder therapies; Dimethylamines; Drug withdrawal therapies; Ethylamines; Indoles; Organic deuterium compounds; Phenols; Small molecules; Tryptamines
- Mechanism of Action Serotonin 5-HT2A receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Major depressive disorder
- Discontinued Alcoholism; Psychiatric disorders
Most Recent Events
- 09 Mar 2026 Chemical structure information added.
- 10 Dec 2025 Phase-III clinical trials in Major depressive disorder (Adjunctive treatment) in United Kingdom, Ireland, Greece, Australia (PO) (NCT06793397)
- 30 Nov 2025 Cybin initiates a phase III EMBRACE trial in Major Depressive Disorder (Adjunctive treatment) in the USA (PO) (NCT06793397)